Reconcile

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

flúoxetín

Available from:

Forte Healthcare Limited

ATC code:

QN06AB03

INN (International Name):

fluoxetine

Therapeutic group:

Hundar

Therapeutic area:

Sálgreiningarefni

Therapeutic indications:

Sem aðstoð við meðferð á aðskilnaðarsjúkdómum hjá hundum sem koma fram við eyðileggingu og óviðeigandi hegðun (vöðvun og óviðeigandi hægðatregða og / eða þvaglát) og aðeins í samsetningu með hegðunarbreytingum.

Product summary:

Revision: 14

Authorization status:

Leyfilegt

Authorization date:

2008-07-08

Patient Information leaflet

                                14
B. FYLGISEÐILL
15
FYLGISEÐILL:
RECONCILE 8 MG TUGGUTÖFLUR FYRIR HUNDA
RECONCILE 16 MG TUGGUTÖFLUR FYRIR HUNDA
RECONCILE 32 MG TUGGUTÖFLUR FYRIR HUNDA
RECONCILE 64 MG TUGGUTÖFLUR FYRIR HUNDA
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi
FORTE Healthcare ltd
Cougar Lane
Naul
Co. Dublin
Ireland
Framleiðandi sem ber ábyrgð á lokasamþykkt:
Tairgi Tread -Lia Baile na Sceilge Teo T/A Ballinskelligs
Veterinary Products,
Ballinskelligs,
Co. Kerry,
V23 XR52,
Ireland
2.
HEITI DÝRALYFS
Reconcile 8 mg tuggutöflur fyrir hunda
Reconcile 16 mg tuggutöflur fyrir hunda
Reconcile 32 mg tuggutöflur fyrir hunda
Reconcile 64 mg tuggutöflur fyrir hunda
flúoxetín
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
Sérhver tafla inniheldur:
Reconcile 8 mg: flúoxetín 8 mg (sem 9,04 mg flúoxetín
hýdróklóríð)
Reconcile 16 mg: flúoxetín 16 mg (sem 18,08 mg flúoxetín
hýdróklóríð)
Reconcile 32 mg: flúoxetín 32 mg (sem 36,16 mg flúoxetín
hýdróklóríð)
Reconcile 64 mg: flúoxetín 64 mg (sem 72,34 mg flúoxetín
hýdróklóríð)
Reconcile eru doppóttar, ljósbrúnar til brúnar kringlóttar
tuggutöflur með innprentaðri tölu á annari
hliðinni (eins gefið er upp hér fyrir neðan):
Reconcile 8 mg töflur: 4203
Reconcile 16 mg töflur: 4205
Reconcile 32 mg töflur: 4207
Reconcile 64 mg töflur: 4209
16
4.
ÁBENDING(AR)
Notað sem liður í meðferð við vandamálum hjá hundum er
tengjast aðskilnaðarkvíða, s.s.
eyðileggingarhvöt og gelti og losun á saur og þvagi. Lyfið á
einungis að nota samhliða atferlisþjálfun
sem dýralæknirinn hefur mælt með.
5.
FRÁBENDINGAR
Notið ekki handa hundum sem vega minna en 4 kg.
Notið ekki hjá hundum með flogaveiki eða sögu um krampa.
Gefið ekki dýrum sem hafa ofnæmi fyrir flúoxetíni eða öðrum
sértækum serótónín
endurupptökuhemlum (SSRI lyf) eða einhverju hjálparefnanna.
6.
AUKAVERKANIR
Til að draga eins og kostur er úr hættu á aukaverkun
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
2
1.
HEITI DÝRALYFS
Reconcile 8 mg tuggutöflur fyrir hunda
Reconcile 16 mg tuggutöflur fyrir hunda
Reconcile 32 mg tuggutöflur fyrir hunda
Reconcile 64 mg tuggutöflur fyrir hunda
2.
INNIHALDSLÝSING
Hver tafla inniheldur:
VIRK INNIHALDSEFNI:
Reconcile 8 mg: Flúoxetín 8 mg (samsvarandi 9,04 mg flúoxetín
hýdróklóríð)
Reconcile 16 mg: Flúoxetín 16 mg (samsvarandi 18,08 mg flúoxetín
hýdróklóríð)
Reconcile 32 mg: Flúoxetín 32 mg (samsvarandi 36,16 mg flúoxetín
hýdróklóríð)
Reconcile 64 mg: Flúoxetín 64 mg (samsvarandi 72,34 mg flúoxetín
hýdróklóríð)
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Tuggutafla.
Doppóttar, ljósbrúnar til brúnar kringlóttar tuggutöflur, með
númer greypt í aðra hliðina (eins og fram
kemur hér fyrir neðan):
Reconcile 8 mg töflur: 4203
Reconcile 16 mg töflur: 4205
Reconcile 32 mg töflur: 4207
Reconcile 64 mg töflur: 4209
4.
KLÍNÍSKAR UPPLÝSINGAR
4.1
DÝRATEGUNDIR
Hundar.
4.2
ÁBENDINGAR FYRIR TILGREINDAR DÝRATEGUNDIR
Notað sem liður í meðferð við vandamálum hjá hundum er
tengjast aðskilnaðarkvíða sem lýsir sér
með eyðileggingarhvöt og óeðlilegu atferli (gelti og losun á
saur og þvagi) og aðeins samhliða
atferlisþjálfun.
4.3
FRÁBENDINGAR
Notið ekki handa hundum sem vega minna en 4 kg.
Notið ekki hjá hundum með flogaveiki eða sögu um krampa.
Gefið ekki dýrum sem hafa ofnæmi fyrir flúoxetíni eða öðrum
sértækum serótónín
endurupptökuhemlum (SSRI lyf) eða einhverju hjálparefnanna.
3
4.4
SÉRSTÖK VARNAÐARORÐ FYRIR HVERJA DÝRATEGUND
Engin
4.5
SÉRSTAKAR VARÚÐARREGLUR VIÐ NOTKUN
Sérstakar varúðarreglur við notkun hjá dýrum
Öryggi notkunar Renconcile hjá hundum, sem eru yngri en 6 mánaða
eða vega minna en 4 kg, hefur
ekki verið staðfest.
Hundar í meðferð með lyfinu geta fengið krampa þó að það sé
mjög sjaldgæft. Stöðva skal meðferðina
ef krampar koma fyrir.
Sérstakar varúðarreglur fyrir þann sem ge
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-06-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-06-2021
Public Assessment Report Public Assessment Report Bulgarian 19-10-2016
Patient Information leaflet Patient Information leaflet Spanish 16-06-2021
Public Assessment Report Public Assessment Report Spanish 19-10-2016
Patient Information leaflet Patient Information leaflet Czech 16-06-2021
Public Assessment Report Public Assessment Report Czech 19-10-2016
Patient Information leaflet Patient Information leaflet Danish 16-06-2021
Public Assessment Report Public Assessment Report Danish 19-10-2016
Patient Information leaflet Patient Information leaflet German 16-06-2021
Public Assessment Report Public Assessment Report German 19-10-2016
Patient Information leaflet Patient Information leaflet Estonian 16-06-2021
Public Assessment Report Public Assessment Report Estonian 19-10-2016
Patient Information leaflet Patient Information leaflet Greek 16-06-2021
Public Assessment Report Public Assessment Report Greek 19-10-2016
Patient Information leaflet Patient Information leaflet English 16-06-2021
Public Assessment Report Public Assessment Report English 19-10-2016
Patient Information leaflet Patient Information leaflet French 16-06-2021
Public Assessment Report Public Assessment Report French 19-10-2016
Patient Information leaflet Patient Information leaflet Italian 16-06-2021
Public Assessment Report Public Assessment Report Italian 19-10-2016
Patient Information leaflet Patient Information leaflet Latvian 16-06-2021
Public Assessment Report Public Assessment Report Latvian 19-10-2016
Patient Information leaflet Patient Information leaflet Lithuanian 16-06-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-06-2021
Public Assessment Report Public Assessment Report Lithuanian 19-10-2016
Patient Information leaflet Patient Information leaflet Hungarian 16-06-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 16-06-2021
Public Assessment Report Public Assessment Report Hungarian 19-10-2016
Patient Information leaflet Patient Information leaflet Maltese 16-06-2021
Public Assessment Report Public Assessment Report Maltese 19-10-2016
Patient Information leaflet Patient Information leaflet Dutch 16-06-2021
Public Assessment Report Public Assessment Report Dutch 19-10-2016
Patient Information leaflet Patient Information leaflet Polish 16-06-2021
Public Assessment Report Public Assessment Report Polish 19-10-2016
Patient Information leaflet Patient Information leaflet Portuguese 16-06-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 16-06-2021
Public Assessment Report Public Assessment Report Portuguese 19-10-2016
Patient Information leaflet Patient Information leaflet Romanian 16-06-2021
Public Assessment Report Public Assessment Report Romanian 19-10-2016
Patient Information leaflet Patient Information leaflet Slovak 16-06-2021
Public Assessment Report Public Assessment Report Slovak 19-10-2016
Patient Information leaflet Patient Information leaflet Slovenian 16-06-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 16-06-2021
Public Assessment Report Public Assessment Report Slovenian 19-10-2016
Patient Information leaflet Patient Information leaflet Finnish 16-06-2021
Public Assessment Report Public Assessment Report Finnish 19-10-2016
Patient Information leaflet Patient Information leaflet Swedish 16-06-2021
Public Assessment Report Public Assessment Report Swedish 19-10-2016
Patient Information leaflet Patient Information leaflet Norwegian 16-06-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 16-06-2021
Patient Information leaflet Patient Information leaflet Croatian 16-06-2021
Public Assessment Report Public Assessment Report Croatian 19-10-2016

Search alerts related to this product

View documents history